AC Immune (ACIU) CEO discloses equity and option holdings

Rhea-AI Filing Summary

AC Immune SA Chief Executive Officer Andrea Pfeifer filed an initial statement of beneficial ownership, reporting 3,840,288 Common Shares held directly and 14,000 Common Shares held indirectly by her spouse. The direct position includes 1,921,005 Common Shares underlying outstanding restricted share units.

The filing also lists several fully vested share options over Common Shares with exercise prices between 2.03 and 9.53 per share and expiration dates from 2027 through 2032, providing a detailed snapshot of the CEO’s current equity-based incentives.

Insider Trade Summary

9 transactions reported

Mixed 9 txns

Insider Pfeifer Andrea

Role Chief Executive Officer

Type	Security	Shares	Price	Value
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Common Shares	--	--	--
holding	Common Shares	--	--	--

Holdings After Transaction: Share Option (right to buy) — 102,811 shares (Direct); Common Shares — 3,840,288 shares (Direct); Common Shares — 14,000 shares (Indirect, By spouse)

Footnotes (1)

1. Includes 1,921,005 common shares underlying outstanding restricted share units. The share option is fully vested.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Pfeifer Andrea

(Last) (First) (Middle)

EPFL INNOVATION PARK, BUILDING B

(Street)

LAUSANNE 1015

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
AC Immune SA [ ACIU ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Shares	3,840,288(1)	D
Common Shares	14,000	I	By spouse

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	(2)	07/01/2027	Common Shares	102,811	$9.53	D
Share Option (right to buy)	(2)	10/28/2028	Common Shares	132,075	$8.51	D
Share Option (right to buy)	(2)	06/27/2029	Common Shares	132,837	$5.39	D
Share Option (right to buy)	(2)	06/25/2030	Common Shares	174,251	$6.95	D
Share Option (right to buy)	(2)	06/24/2031	Common Shares	218,216	$7.23	D
Share Option (right to buy)	(2)	06/23/2032	Common Shares	172,500	$3.15	D
Share Option (right to buy)	(2)	12/31/2032	Common Shares	644,444	$2.03	D

Explanation of Responses:

1. Includes 1,921,005 common shares underlying outstanding restricted share units.

2. The share option is fully vested.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Matthias Maurer, attorney-in-fact for Andrea Pfeifer	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does AC Immune (ACIU) CEO Andrea Pfeifer report in this Form 3?

Andrea Pfeifer reports her initial equity holdings in AC Immune. She lists 3,840,288 Common Shares held directly, 14,000 Common Shares held indirectly through her spouse, plus multiple fully vested share options over additional Common Shares with specified exercise prices and expiration dates.

How many AC Immune (ACIU) shares does the CEO hold directly and indirectly?

The CEO holds 3,840,288 shares directly and 14,000 indirectly. The indirect shares are held by her spouse, while the direct position includes 1,921,005 Common Shares underlying outstanding restricted share units, as disclosed in the footnotes.

What restricted share units does AC Immune (ACIU) disclose for its CEO?

The filing states that 1,921,005 Common Shares are underlying restricted share units. These RSUs are included within Andrea Pfeifer’s direct holding of 3,840,288 Common Shares, highlighting a significant component of her equity-based compensation.

What share options are reported for the AC Immune (ACIU) CEO?

The CEO holds several fully vested share options over Common Shares. Exercise prices range from 2.03 to 9.53 per share, with option expiration dates running from 2027 through 2032, outlining a long-dated incentive structure tied to future share performance.

Does this AC Immune (ACIU) Form 3 show any recent share purchases or sales?

The Form 3 functions as an initial ownership report, not a trade record. The transactions are coded as holdings with unknown transaction direction, indicating this disclosure establishes Andrea Pfeifer’s existing positions rather than documenting new purchases or sales.